NCT05323045View on ClinicalTrials.gov

A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

March 4, 2024

Study Completion Date

September 25, 2024

Conditions
Solid Tumor
Interventions
DRUG

BYON3521

BYON3521 (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.

Trial Locations (4)

1070

Istituto Europeo di Oncologia, Milan

Unknown

Institut Jules Bordet, Brussels

6500HB

Radboud, Nijmegen

SM2 5PT

Royal Marsden, London

Sponsors

Lead Sponsor

Byondis B.V.
All Listed Sponsors
lead

Byondis B.V.

INDUSTRY

NCT05323045 - A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 | Biotech Hunter | Biotech Hunter